The Food and Drug Administration (FDA) said 23 out of 163 potential vaccines for coronavirus disease (COVID-19) are currently under clinical testing stage.
According to FDA Director General Eric Domingo, two potential COVID-19 vaccines will be given to a larger group of people to see if it is effective and to further evaluate its safety.
The said vaccines are Astrazeneca, currently being developed in London, and Sinovac that is being developed in China.
Department of Health (DOH) Spokesperson Usec. Maria Rosario Vergeire said that the anti-flu drug Favipiravir or Avigan, from Japan is also nearing clinical trials.
“We are fortunate that the Japanese have reached out to us to help increase the sample size of their Avigan drug trial, a potential treatment to prevent people from dying from COVID-19,” she said.
Meanwhile, the FDA has confirmed that another potential vaccine is being developed in Russia. Domingo said it is currently in the advanced phase.
“Ginagamit na rin siya sa clinical trial ng ibang bansa mayroon din sa Japan, China, United States, Italy at Russia, (It is currently under clinical trial in other countries like Japan, China, United States, and Russia),” he said.
The medicine for Ebola Virus, Remdesivir, is currently under solidarity trial. Remdesivir is being used in other countries to treat severe COVID-19 patients. AAC (with reports from Aiko Miguel)
The post 23 out of 163 potential COVID-19 vaccines under clinical trial—FDA appeared first on UNTV News.